Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Eribulin is a recommended treatment option for locally advanced or metastatic breast cancer (LABC/MBC) in adults whose disease has progressed after at least two chemotherapy regimens. The National Institute for Health and Care Excellence (NICE) invited the manufacturer of eribulin (Halaven(®); Eisai...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleeman, Nigel, Bagust, Adrian, Duarte, Rui, Richardson, Marty, Nevitt, Sarah, Boland, Angela, Kotas, Eleanor, McEntee, Joanne, Thorp, Nicky
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710448/
https://www.ncbi.nlm.nih.gov/pubmed/30742256
http://dx.doi.org/10.1007/s41669-018-0114-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710448/
https://www.ncbi.nlm.nih.gov/pubmed/30742256
http://dx.doi.org/10.1007/s41669-018-0114-z

Ejemplares similares